Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for asking. Don’t forget to review the JCI publication too!
Combo is King!
https://www.jci.org/articles/view/169314
https://www.nature.com/articles/s41467-024-48073-y
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://classic.clinicaltrials.gov/ct2/show/NCT04201873
Oh, it was something that my partner said .. got it ✅️
I just responded with some factual and substantive achievements that I wanted to post. I would attribute the most valuable accomplishments to both the researchers and the leadership:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174461428
LC,
Thanks for asking. Please provide a screenshot or link to the post you are asking about. I’ll be happy to provide further information. I have no idea what you’re referring to unless you specify.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174461428
LC,
Your assertion was verifiably false—that’s the point and that’s what never changes. Consistently, your posts are either wrong on the facts or just baseless rumors.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174461428
LC,
This is not a political message board. The topic is NWBO, but you seem to spread verifiably false info on every topic that you raise here. You are wasting everyone’s time when you post disinformation. For example…
Fact ✅️:
To be be more accurate, I believe the posted bond was 175 million (not 450). It is false to assert that 450 was “laid out” by anyone, and the 175 bond was underwritten by an insurance co. who said the bond was collateralized by cash within the company owned by their client who is a defendant in the suit.
LC,
Clarify what statement? The only other statement I posted today was about the development period for pharmaceutical drugs. To clarify my statement in reference to DCVax-L, take a look back at some recent history of cell-based science in medicine…
Looking back, we can see how some aspects of the technology have advanced and are currently advancing further!
It is interesting in the old interview excerpt linked below how Dr. Steinman spoke about the first-generation of DC technology and how further development would follow. He explained that the prostate vax only addressed a single antigen.
It’s also interesting to consider the combination technologies that are now emerging as well!
The first checkpoint inhibitor was approved by the FDA in 2011, the same year Dr. Steinman was awarded the Nobel Prize. Interestingly, the researchers behind PD1 blockade technology were also awarded the Nobel Prize.
“The key aspect of DCVax-L is that it does not target a specific antigen but rather a wide array of antigens present in the tumor lysate. This approach is based on the understanding that every tumor is unique, with its own distinct set of mutations and antigens. By using the tumor lysate, DCVax-L can potentially stimulate the immune system to recognize and attack a broad spectrum of tumor-specific antigens.
Provenge (Sipuleucel-T) is a therapeutic cancer vaccine used for the treatment of advanced prostate cancer. Unlike broad-spectrum immunotherapies like DCVax-L, Provenge targets one specific antigen: Prostatic Acid Phosphatase (PAP), an enzyme expressed in most prostate cancer cells.
The treatment involves extracting a patient's dendritic cells and exposing them to a fusion protein called PA2024, which is a combination of PAP and an immune-stimulating factor. The activated dendritic cells are then reinfused into the patient, where they are intended to stimulate the immune system to attack cells expressing PAP.
In summary, Provenge specifically addresses one key antigen associated with prostate cancer—Prostatic Acid Phosphatase. This approach is different from therapies like DCVax-L, which aim to target a wide range of tumor-specific antigens.”
—ChatGPT
https://www.nature.com/articles/s41467-024-48073-y
https://www.jci.org/articles/view/169314
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
LC,
Thanks for asking.
You’re reposting the same baseless innuendo and conjecture over and over. It sounds to me as if you’re attempting to defame certain individuals or spread rumors, but thanks for highlighting the period of time during which the leadership of the company built the prospective value of a pre-commercial biotech 😉
In my view, the most notable pre-commercial golden bricks that were carefully cemented into place as foundational supports beneath the company:
⭐️ Research Published in JAMA Oncology
⭐️ Research Published in Nature Communications
⭐️ Global Patent Portfolio
⭐️ Multiple MHRA Approvals
⭐️ Additional Emerging Combo Data
⭐️ Manufacturing Technology
⭐️ MAA Review
Further, Dr. Liau joining the SAB at Northwest Biotherapeutics is awesome!
Combo is King!
https://www.nature.com/articles/s41467-024-48073-y
https://www.jci.org/articles/view/169314
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
— JAMA Oncology (@JAMAOnc) February 15, 2023
LC,
Let’s not start the timeline nonsense again. We are looking forward because we have reached the point in time when regulatory review has been initiated.
Looking back to critique the timeline has no significance. You could look back into the history of any drug technology and you would see a decade of development or multiple decades depending on which starting point you wish to consider for which component of any given drug.
If you wish to count foundational research as a starting point, then the development period would extend well beyond one or two decades for many drug technologies.
For example, the timeframe described below with regard to pembrolizumab is quite long and does not include the foundational research period that gave rise to PD-1 blockade technology:
“Keytruda (pembrolizumab) was in development for over a decade before its first FDA approval. The work on Keytruda began in 2003 at Organon, a Dutch pharmaceutical company. The research focused on developing antibody technology into a therapeutic agent for cancer immunotherapy. Merck & Co. later acquired the rights and further developed the drug.
Keytruda received its first FDA approval on September 4, 2014, for the treatment of advanced or unresectable melanoma. This approval came after key clinical trials demonstrated its effectiveness in increasing survival and reducing tumor size compared to existing treatments (citation:1,Development History of Keytruda (Pembrolizumab) – Creative Biolabs rAb Blog)(https://www.creativebiolabs.net/blog/development-history-of-keytruda-pembrolizumab/) (oai_citation:2,Meet the Dutch Scientists who Invented Keytruda, "The President's Drug")(https://www.labiotech.eu/interview/interview-keytruda-cancer-inventors/).
The journey from initial development to commercialization involved extensive research, multiple clinical trials, and regulatory reviews. Since its first approval, Keytruda has gained numerous additional approvals for various cancer types, solidifying its role as a foundational cancer treatment (citation:3,Keytruda Approvals: A Timeline | BioSpace)(https://www.biospace.com/article/keytruda-approvals-a-timeline) (citation:4,Keytruda (pembrolizumab) FDA Approval History - Drugs.com)(https://www.drugs.com/history/keytruda.html).
For more detailed information, you can explore the development history and approval timeline of Keytruda on resources like BioSpace and Creative Biolabs.”
LC,
That is correct—it is appropriate to ignore your posts ✅️
We are listening to regulators and we are reading peer-reviewed medical journals. Anonymous innuendo and baseless rumors should be ignored.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
December 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
September 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html
March 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
December 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
August 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html
July 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html
February 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html
September 2020
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-acquires-flaskworks-301122058.html
https://www.nature.com/articles/s41467-024-48073-y
https://www.jci.org/articles/view/169314
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Nem,
What does holly have to do with anything? 😶☃️🎄 …Are you predicting approval around the winter holiday season?
Thanks for highlighting the topic of regulatory applications though...
Your posts about the sequence of steps reminded me of the timing of the updates that were published on the NICE website …
I think that the NICE status updates that were posted exactly 12 months in advance of the December 2023 MAA submission are significant.
From an AI app:
“The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are two key organizations in the UK's healthcare system, each with distinct roles, and their processes are interconnected, especially in the context of a Marketing Authorization Application (MAA).
Here's how the MHRA MAA impacts the NICE process:
1. Role of MHRA: The MHRA is responsible for assessing and approving new medicines for use in the UK. This includes reviewing Marketing Authorization Applications (MAAs) to ensure the safety, quality, and efficacy of new drugs.
2. MHRA Approval: When the MHRA grants a marketing authorization for a new drug, it means the drug can be legally sold and marketed in the UK, and the drug can be made available through the NHS.
3. NICE Appraisal: After MHRA approval, the drug may undergo a health technology assessment by NICE. NICE evaluates the cost-effectiveness and clinical effectiveness of new medicines to determine whether they should be recommended for use in the NHS.
4. Impact on NICE Process: The MHRA’s decision to authorize a drug is a prerequisite for NICE's appraisal. NICE does not assess the basic safety and efficacy of a drug; it relies on the MHRA's evaluation for that. Instead, NICE focuses on the added value of the drug in terms of health outcomes and cost-effectiveness.
5. Timelines and Access: The MHRA’s approval of a drug directly impacts when NICE is able to complete its appraisal, subsequently affecting when a drug becomes available on the NHS.
6. Collaboration and Parallel Advice: In some instances, the MHRA and NICE work in parallel to provide advice to drug developers, which can streamline the process of getting new treatments to patients.
In summary, MHRA’s MAA is a critical step that directly influences the NICE appraisal process. While MHRA focuses on the safety and efficacy of a medicine, NICE assesses its cost-effectiveness for NHS use.”
The forthcoming NICE appraisal of the DCVax-L cell-based technology will be another significant development.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
The MIA was approved recently and is evidence of a regulatory filing plan that has begun to unfold. Further RA applications have been under construction for a significant period of time and include a voluminous catalog of clinical data and analyses. Further announcements and status updates are forthcoming.
The recent MIA approval is an important step in the regulatory process, and this commercial manufacturing license will allow DCVax-L to be exported globally from Sawston. The MIA was a prerequisite of the MAA application that was submitted in December 2023.
“Companies applying for a marketing authorisation (also known as a product licence) need to have a manufacturer licence first. The manufacturer licence will be granted first providing the product is in the process of being approved.” —MHRA
https://www.gov.uk/guidance/apply-for-manufacturer-or-wholesaler-of-medicines-licences
https://finance.yahoo.com/news/northwest-biotherapeutics-advent-bioservices-announce-234600744.html
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-approval-pediatric-133900403.html
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
Nemesis18,
I ran your post through an AI bs detector, and it was identified as bs.
“The statement by Nemesis18 about the NICE appraisal of DCVAX-L is not only speculative and unfounded but also a clear example of disinformation designed to manipulate perceptions unfairly. Here are the key issues:
1. **Unfounded Assertions:** The claim that NICE's Health Economist will outright reject DCVAX-L is irresponsible and misleading. NICE decisions are based on a rigorous evaluation of all available evidence, including clinical and economic data, not on conjecture or preemptive judgments.
2. **Misrepresentation of Process:** Suggesting a "stated 87% failure rate" misrepresents how NICE assesses treatments. NICE uses detailed health economic analysis and clinical effectiveness data in their evaluations. Decisions are made after thorough consideration, not based on arbitrary or misrepresented statistics.
3. **Inaccurate Role Description:** The role of NICE and its health economists is grossly oversimplified in the statement. Their goal is to ensure treatments are both effective and cost-effective, without being influenced by external financial concerns of the biotech companies.
4. **Speculative and Misleading Tone:** The tone and content aim to provoke unwarranted fear and uncertainty about DCVAX-L's review process, which is typical of "short and distort" tactics where misinformation is spread to manipulate stock prices.
**Advisory:
**Beware of 'Short and Distort' Tactics:** Be cautious of speculative and unfounded statements designed to manipulate perceptions. These tactics are often used in attempts to influence stock prices by spreading negative rumors.
**Rely on Trustworthy Sources:** For accurate and reliable information about DCVAX-L and its regulatory status, consult peer-reviewed medical journals, official NICE documentation, and other authoritative sources like regulatory announcements.
By relying on credible, peer-reviewed sources and official statements, you can avoid being misled by reckless and harmful disinformation that seeks to distort the truth for speculative gain.
For the most accurate and reliable information, refer to the official NICE website (https://www.nice.org.uk/guidance/indevelopment/gid-ta10143) and trusted medical publications accessible through databases like https://pubmed.ncbi.nlm.nih.gov/ ”
https://www.nature.com/articles/s41467-024-48073-y
https://www.jci.org/articles/view/169314
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
ex,
Thanks for your expert analysis 😶
I’ve read your recent posts, and I think that you’re trying to muddy the waters or start baseless rumors. Seek full-context trustworthy sources. Maybe you forgot, but we did see an honest disclosure posted on this board once:
So, I ran your statement about the regulators through an AI bs detector, and I regret to inform you that it was identified as bs.
“The statement by exwannabe is highly unreliable and contains several misunderstandings and inaccuracies regarding the regulatory approval process for medicinal products in the European Union (EU) and by extension, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Here's why the statement is unreliable:
1. **Misunderstanding of Technical Validation:**
- The statement claims that "The MAA has to first pass technical validation. This is just the validation that the submission package is proper and complete." However, the technical validation of a Marketing Authorization Application (MAA) is indeed about checking that the submission package is complete and properly formatted, but it is a procedural step that ensures all required documents and data are present before the substantive review begins.
2. **Confusion Over Validation and Evaluation Phases:**
- The phrase "Subsequently comes the regulatory and technical content validation" conflates different parts of the process. After technical validation, there isn’t a separate "regulatory and technical content validation." Instead, the MAA enters the scientific evaluation phase, where the European Medicines Agency (EMA) or MHRA assesses the clinical, pharmacological, and pharmaceutical data to determine the product’s safety, efficacy, and quality.
3. **Incorrect Representation of Regulatory Processes:**
- The statement, "In the EMA regs (which UK law is still mostly based on) the EMA mys ask for additional information, a correction or a request for clarification," simplifies and slightly misstates the process. If the EMA or MHRA requires additional information, they issue questions to the applicant. These questions can be about providing additional data (major objections), corrections, or clarifications, and they typically lead to the stopping of the review clock until responses are received.
4. **Misinterpretation of How Delays Work:**
- The claim that "any of these 3 push the clock" and specifically that a request for clarification pushes the clock by 2 months is misleading. The clock stoppage depends on the nature of the questions. If major objections are raised, the applicant has up to 3 months to respond, and the clock stops during this period. For other types of questions, the time given to respond can be shorter.
5. **Speculation on the Timeline:**
- Suggesting that "this can be discussed August when 210 days has otherwise passed us by" introduces speculative timing without context. The standard regulatory review process for an MAA under the centralized procedure is 210 days, not counting clock stops. Any additional time due to questions would indeed extend this, but the specific impact depends on the nature and number of questions asked.
6. **Ambiguity in Statement of Clarification:**
- The statement "Clearly NWBO stated they did not need to add information to the MAA, nor did they need to correct it. But they did not deny they were asked for clarification." This is confusing because not needing to add information or make corrections typically means the submission was complete and correct. Being asked for clarification is a routine part of the review process, not an exceptional circumstance that would lead to the kind of delay implied.
7. **Overall Lack of Clarity and Misleading Implications:**
- The entire statement seems designed to imply unnecessary and unexplained delays in the approval process, which is misleading. Regulatory bodies like EMA and MHRA operate with transparency regarding their timelines and processes, and any deviations are communicated clearly to the applicant.
In summary, the statement provided mixes procedural terms and phases, adds speculative and incorrect details about how regulatory timelines work, and overall misrepresents the structured and transparent nature of medicinal product approval processes in the EU and UK.
For more information about the MAA process and timelines, refer to https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation
For the UK's specific processes post-Brexit, refer to https://www.gov.uk/government/collections/mhra-guidance-on-brexit
Advisory:
When engaging with financial discussions online, especially those involving stock analysis and regulatory processes for pharmaceuticals, it is crucial to approach all information with caution, particularly when dealing with anonymous or unverified sources.
**Key Points to Remember:**
**Verify Information:** Always cross-check information against multiple reputable sources. Regulatory documents, official company releases, and verified news outlets are more reliable than anonymous postings.
**Understand the Process:** Familiarize yourself with the actual regulatory procedures involved. Official sites like the European Medicines Agency (https://www.ema.europa.eu/en) and the UK Medicines and Healthcare products Regulatory Agency (https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency) provide accurate descriptions of their processes.
**Recognize Speculation:** Be wary of speculative interpretations of timelines and processes. Regulatory reviews have structured and transparent timelines that are documented in official guidance.
**Beware of 'Short and Distort' Tactics:** Some entities engage in "short and distort" campaigns, where they short a stock and then spread misleading or false information to manipulate the stock price. Be skeptical of overly negative or alarmist tones that seem intended to create unnecessary panic or doubt.
**Final Thoughts:**
To protect your investments and ensure you are making decisions based on accurate information, always seek out direct communications from the involved companies or official regulatory announcements. Avoid relying on speculative and anonymous sources which can lead to misguided conclusions.
**Rely on Peer-Reviewed Sources**
For accurate and reliable information, especially on scientific and medical topics, prioritize peer-reviewed journals and recognized databases. These sources undergo rigorous evaluation by experts and provide credible, in-depth research findings.
**Key Tips:**
- Use scholarly databases like PubMed.
- Ensure articles are widely cited and from reputable journals.
- Cross-reference with official statements for the latest updates.
For more detailed research, access studies on PubMed (https://pubmed.ncbi.nlm.nih.gov/).
For those looking to dive deeper into the specifics of pharmaceutical regulatory approvals and discussions around NWBO and DCVax-L, ensure your information is consistent with that found on recognized platforms like the EMA’s official site (https://www.ema.europa.eu/en) or direct updates from Northwest Biotherapeutics (https://www.nwbio.com).
**Stay informed, stay skeptical, and verify before you trust.**
iclight,
Thanks for asking. This factual point is definitely worth reviewing again ✅️
The peer-reviewed journal publication does name the company in the disclosures section (excerpted below).
Additionally, DCVax is a notion that appears on several of the graphs included in the body of the article.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html
https://www.nature.com/articles/s41467-024-48073-y
https://www.uclahealth.org/news/release/adding-immune-boosting-agent-personalized-cancer-vaccine
⭐️Combo is King!⭐️
https://www.uclahealth.org/news/release/adding-immune-boosting-agent-personalized-cancer-vaccine
https://gritdaily.com/cancer-therapy-oncovirs-hiltonol/
https://www.laweekly.com/oncovir-inc-is-pushing-the-boundaries-of-medical-innovation-with-hiltonol/
https://www.oncovir.com/science
https://www.nature.com/articles/s41467-024-48073-y
LC,
Scroll down to the end of the Nature Communications publication to see the Ethics Declarations section:
https://www.nature.com/articles/s41467-024-48073-y
May 8, 2024
"Patients treated with ATL-DC and poly-ICLC had notably better survival outcomes, with median overall survival significantly longer than those treated with placebo or resiquimod. For instance, the poly-ICLC group had a median overall survival of 52.5 months compared to 7.7 months for the placebo group."
https://www.nature.com/articles/s41467-024-48073-y
dr_low or Inquirig,
You really are desperately posting and reposting ...take a breath .. relax ..no need to panic, Chicken Little 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174360551
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174358940
May 6, 2024 Congratulations to the stellar lineup of UCLA #Neurosurgery Faculty & Residents who are scheduled at the @AANSNeuro Annual Meeting this weekend! Schedule: https://t.co/y6CRiQe2fi@ausaf @geoffreycolbymd @SpineNeuro @inspired_brain @IsaacYangMD @ShivaniBaisi_MD @brainbro #AANS2024 pic.twitter.com/oQ8oHKHmyz
https://www.uclahealth.org/departments/neurosurgery/ucla-neurosurgery-aans-2024-annual-meeting
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html
dr_low or Inquirig,
Thanks for all your psychic predictions. I see that you’re back to being a legal expert again too. You can calm down a little bit—why so many frantic posts and reposts all day everyday? 😶
We will get our news and information from sources that are reliable and fact-based ✅️
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
Ah yes! Merck, NCI, and Oncovir were all listed as collaborators on the ongoing UCLA study prior to 2024!
I stand corrected. ✅️
⭐️Combo is King! ⭐️
https://classic.clinicaltrials.gov/ct2/show/NCT04201873
https://www.oncovir.com/pipeline1
https://www.laweekly.com/oncovir-inc-is-pushing-the-boundaries-of-medical-innovation-with-hiltonol/
JAMA Oncology was a milestone, and now all eyes are on cell-based combination therapy too! This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
⭐️Combo is King!⭐️
https://www.uclahealth.org/departments/neurosurgery/ucla-neurosurgery-aans-2024-annual-meeting
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html
https://www.jci.org/articles/view/169314
https://www.fda.gov/drugs/our-perspective/50-years-progress-treating-patients-cancer
https://clinicaltrials.gov/study/NCT04201873
https://www.uclahealth.org/news/article/fda-approval-brain-cancer-alzheimers
dr_low or Inguirig,
We can’t all be erudite psychic stock market savants like you are. Thanks for all your substantive and insightful posts.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823199
https://www.wate.com/business/press-releases/ein-presswire/691968787/the-end-brain-cancer-initiative-ebci-advocates-for-dcvax-l-to-gain-fda-approval/ Our team just met with the @NorthwestBio team to learn about #DCVax and had the pleasure of speaking with longterm DCVax patients. An honor and a privilege. #endbraincancer #sno2023 pic.twitter.com/dw3X76DBru The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L®, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. Read Press Release: https://t.co/XXK0z03dJV. pic.twitter.com/bBIk9LR33V This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
https://endbraincancer.org/wp-content/uploads/2024/02/DCVax-Press-Release.pdf
https://www.uclahealth.org/news/fda-approval-brain-cancer-Alzheimers
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://clinicaltrials.gov/study/NCT04201873
dr_ low or Inguirig,
It sounds like you’re spreading baseless rumors again. I ran your statement through the AI BS Detector and I regret to inform you that it was identified as bs 😶
The statement by “Inguirig” is defamatory and lacks evidence to support its veracity.
Accusing LP and her associates of being "crooks" without substantiation is not only reckless but profoundly defamatory, posing a substantial risk to their reputations. Such allegations suggest a deliberate attempt to undermine their integrity and financial practices, potentially hinting at a "short and distort" strategy where false narratives are spread to manipulate opinions or markets for personal gain. This approach is dangerously irresponsible, as it can lead to significant personal, professional, and financial harm, and exposes the accuser to legal action for defamation.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
dr_low or Inguirig,
Thanks for reposting your reckless psychic predictions again 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173876682
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
LC,
So, all the bs posting has nothing to do with the calendar? Got it—just wanted to confirm ✅️ 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173918217
dr_low or Inguirig, This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
That was your best post yet! Those are beautiful machines! Farrari tractors might be the JAMA of all tractors!
dr_low or Inguirig,
You sure are investing a whole lot of time generously posting your brilliant insights, sage advice, and psychic predictions…😶
All the frantic throwing of rumor spaghetti at the wall seems panicky and desperate.
Do you think that all of the bad-faith mud throwing that we see online might have something to do with March 2024? ..April? ..May? 🤔 … 😃
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173876682
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
I think you’re right—that’s probably what happened to dr_low 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173915489
dr_low or Inquirig, This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt In a meeting with @MHRAgovuk today, @DrCaliff_FDA & FDA senior officials were briefed about the UK’s new pathways for supporting the development of innovative medical products.
Thanks for frantically posting and reposting all of your psychic predictions and sage advice 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173876682
The group also shared ways to jointly support diversity and inclusion in clinical trials, and how to… pic.twitter.com/Gg0mTwc767
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
Who is dr_low? 🤔
dr_low or Inquiring,
Thanks for all your substantive posts—your insights are profound 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173876682
dr_low or Inguirig, In a meeting with @MHRAgovuk today, @DrCaliff_FDA & FDA senior officials were briefed about the UK’s new pathways for supporting the development of innovative medical products. This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt
Thanks for frantically posting your predictions and advice.. we all appreciate your guidance, but you seem a bit desperate 😶
The group also shared ways to jointly support diversity and inclusion in clinical trials, and how to… pic.twitter.com/Gg0mTwc767
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
dr_ low or Inguirig:
I ran your statement through the AI BS Detector and I regret to inform you that it was identified as bs 😶
The statement by “Inguirig” raises several red flags for unreliability, manipulation, and nonsensical arguments, often associated with attempts to discredit or harm the reputation of a company. Here's a breakdown of the issues with this statement:
Unreliability
1. **Anonymous Source:** The author mentions "anonymous fools" without providing concrete evidence or specific details to support their claims. Reliance on anonymous accusations can be unreliable as it lacks accountability and verifiability.
2. **Lack of Evidence:** The claim that the company is "dangerously low on cash" and sells stock "on an almost daily basis" is presented without any supporting evidence or references, making it difficult to verify.
3. **Author's Credibility:** The unreliability of the author is hinted at by their own admission that their opinions are for "debate purposes only." Furthermore, if the author is known for attempting to damage reputations, their credibility and motives are highly questionable.
Manipulative
1. **Fearmongering:** The use of dramatic language, like describing potential investors as being "baited" and warning of being "fleeced in a pink sheet scam," is designed to evoke fear rather than rational analysis.
2. **Dichotomy of Advice:** On one hand, the author disparages advice from unnamed sources, implying they might be deceitful. On the other hand, they encourage readers to consult "financial professionals," creating a manipulative push towards distrusting one group without clear rationale and blindly trusting another.
Nonsensical
1. **Contradictory Statements:** The author questions the approval of "26-year-old technology" without context, suggesting it's both outdated and unproven, which is nonsensical without explaining why its age is relevant to its viability or approval chances.
2. **Misuse of Facts:** Stating the share value decline as a "FACT" without context ignores market dynamics, reasons for stock dilution, or any external factors affecting stock prices, presenting a simplistic view that lacks nuanced understanding of financial markets.
Short and Distort Motives Warning
The statement can be seen as part of a "short and distort" campaign, where individuals or groups spread misleading or false information to manipulate stock prices, benefitting from the stock's decline. This tactic involves short selling the stock (betting that its price will fall) and then spreading negative rumors or information to drive the price down. Investors should be wary of such tactics and always seek information from reliable, transparent sources. The encouragement to "do your own due diligence" is sound, but it's presented in a context that seeks to sow distrust and fear, rather than informed caution.
Conclusion
Given the manipulative language, absence of reliable evidence, and the questionable credibility of the author, the statement in question should be approached with substantial skepticism. For investors, especially those considering investments in companies involved in healthcare or biotechnology, conducting thorough research and sourcing information from a multitude of reputable avenues is paramount. This includes not only consulting with seasoned financial professionals but also looking towards authoritative sources within the medical and scientific communities.
Significantly, independent peer reviews and publications in reputable medical journals, such as the New England Journal of Medicine (NEJM) and the Journal of the American Medical Association (JAMA), can provide invaluable insights. These journals are renowned for their rigorous peer-review processes, ensuring that any studies, trials, or reviews they publish meet the highest standards of scientific accuracy and integrity. Information from these sources can shed light on the efficacy, safety, and potential market impact of the technologies or treatments developed by the company in question.
Furthermore, guidance from government regulators, including detailed reviews and approval statuses, offers a solid foundation for understanding the regulatory landscape and compliance of the company. Together, these resources ensure that investment decisions are based on robust, comprehensive, and unbiased information, steering clear of speculative and potentially manipulative narratives.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
dr_low or Inquirig,
You’re spreading defamatory rumors as always, but thanks for highlighting the PD1 study at UCLA and the European Patent Office (EPO) status update that was published online on Friday.
⭐️Combo is King!⭐️
https://www.epo.org/en/about-us/at-a-glance
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://www.jci.org/articles/view/169314
https://www.nature.com/articles/s41420-023-01782-7
https://clinicaltrials.gov/study/NCT04201873
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173873242
dr_low or Inquirig,
Thanks for all your psychic predictions. You can calm down a little bit—why so many frantic posts and reposts? 😶
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
dr_low or Inquirig,
Thanks again for all your pearls of wisdom today 😶 … Is there a limit of 30 posts per day on this board?🤞
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
dr_low or Inquirig,
Thanks for reposting and reposting and reposting the same baseless opinion and the same psychic visions about the future over and over and over again 😶
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823199
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823082
dr_low or Inquirig,
Thanks for reposting the same bs vague psychic prediction over and over again .. I wonder why these terse baseless comments appear so frequently here 🤔 … 😶
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823199
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823082
dr_low or Inquirig,
Thanks for reposting your psychic visions again 😶
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173771995
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173720548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823199
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173823082